High affinity soluble ILT2 receptor: a potent inhibitor of CD8⁺ T cell activation

Abstract

Using directed mutagenesis and phage display on a soluble fragment of the human immunoglobulin superfamily receptor ILT2 (synonyms: LIR1, MIR7, CD85j), we have selected a range of mutants with binding affinities enhanced by up to 168,000-fold towards the conserved region of major histocompatibility complex (MHC) class I molecules. Produced in a dimeric form, either by chemical cross-linking with bivalent polyethylene glycol (PEG) derivatives or as a genetic fusion with human IgG Fc-fragment, the mutants exhibited a further increase in ligand-binding strength due to the avidity effect, with resident half-times (t_1/2) on the surface of MHC I-positive cells of many hours. The novel compounds antagonized the interaction of CD8 co-receptor with MHC I in vitro without affecting the peptide-specific binding of T-cell receptors (TCRs). In both cytokine-release assays and cell-killing experiments the engineered receptors inhibited the activation of CD8⁺ cytotoxic T lymphocytes (CTLs) in the presence of their target cells, with sub-nanomolar potency and in a dose-dependent manner. As a selective inhibitor of CD8⁺ CTL responses, the engineered high affinity ILT2 receptor presents a new tool for studying the activation mechanism of different subsets of CTLs and could have potential for the development of novel autoimmunity therapies.

Keywords

CD8⁺ T cells / cellular activation / autoimmunity / cell surface molecules / binding affinity / phage display

References

[1] Bernardeau, K., Gouard, S., David, G., Ruellan, A.L., Devys, A., Barbet, J., Bonneville, M., Cherel, M., and Davodeau, F. (2005). Assessment of CD8 involvement in T cell clone avidity by direct measurement of HLA-A2/Mage3 complex density using a high-affinity TCR like monoclonal antibody. Eur J Immunol 35, 2864–2875 10.1002/eji.200526307.
[2] Binstadt, B.A., Brumbaugh, K.M., Dick, C.J., Scharenberg, A.M., Williams, B.L., Colonna, M., Lanier, L.L., Kinet, J.P., Abraham, R.T., and Leibson, P.J. (1996). Sequential involvement of Lck and SHP-1 with MHC-recognizing receptors on NK cells inhibits FcR-initiated tyrosine kinase activation. Immunity 5, 629–638 10.1016/S1074-7613(00)80276-9.
[3] Borges, L., and Cosman, D. (2000). LIRs/ILTs/MIRs, inhibitory and stimulatory Ig-superfamily receptors expressed in myeloid and lymphoid cells. Cytokine Growth Factor Rev 11, 209–217 10.1016/S1359-6101(00)00007-1.
[4] Buslepp, J., Kerry, S.E., Loftus, D., Frelinger, J.A., Appella, E., and Collins, E.J. (2003). High affinity xenoreactive TCR:MHC interaction recruits CD8 in absence of binding to MHC. J Immunol 170, 373–383 .
[5] Cella, M., Nakajima, H., Facchetti, F., Hoffmann, T., and Colonna, M. (2000). ILT receptors at the interface between lymphoid and myeloid cells. Curr Top Microbiol Immunol 251, 161–166 .
[6] Chang, H.C., Tan, K., and Hsu, Y.M. (2006). CD8alphabeta has two distinct binding modes of interaction with peptide-major histocompatibility complex class I. J Biol Chem 281, 28090–28096 10.1074/jbc.M604931200.
[7] Chapman, T.L., Heikema, A.P., West, A.P. Jr, and Bjorkman, P.J. (2000). Crystal structure and ligand binding properties of the D1D2 region of the inhibitory receptor LIR-1 (ILT2). Immunity 13, 727–736 10.1016/S1074-7613(00)00071-6.
[8] Clackson, T., Hoogenboom, H.R., Griffiths, A.D., and Winter, G. (1991). Making antibody fragments using phage display libraries. Nature 352, 624–628 10.1038/352624a0.
[9] Cole, D.K., Rizkallah, P.J., Sami, M., Lissin, N.M., Gao, F., Bell, J.I., Boulter, J.M., Glick, M., Vuidepot, A.L., Jakobsen, B.K., (2005). Crystallization and preliminary X-ray structural studies of a high-affinity CD8alphaalpha co-receptor to pMHC. Acta Crystallogr Sect F Struct Biol Cryst Commun 61, 285–287 10.1107/S1744309105002988.
[10] Colonna, M., Navarro, F., Bellon, T., Llano, M., Garcia, P., Samaridis, J., Angman, L., Cella, M., and Lopez-Botet, M. (1997). A common inhibitory receptor for major histocompatibility complex class I molecules on human lymphoid and myelomonocytic cells. J Exp Med 186, 1809–1818 10.1084/jem.186.11.1809.
[11] Dunn, S.M., Rizkallah, P.J., Baston, E., Mahon, T., Cameron, B., Moysey, R., Gao, F., Sami, M., Boulter, J., Li, Y., (2006). Directed evolution of human T cell receptor CDR2 residues by phage display dramatically enhances affinity for cognate peptide-MHC without increasing apparent cross-reactivity. Protein Sci 15, 710–721 10.1110/ps.051936406.
[12] Fanger, N.A., Borges, L., and Cosman, D. (1999). The leukocyte immunoglobulin-like receptors (LIRs): a new family of immune regulators. J Leukoc Biol 66, 231–236 .
[13] Fee, C.J., and Van Alstine, J.M. (2004). Prediction of the viscosity radius and the size exclusion chromatography behavior of PEGylated proteins. Bioconjug Chem 15, 1304–1313 10.1021/bc049843w.
[14] Gaberc-Porekar, V., Zore, I., Podobnik, B., and Menart, V. (2008). Obstacles and pitfalls in the PEGylation of therapeutic proteins. Curr Opin Drug Discov Devel 11, 242–250 .
[15] Gao, G.F., and Jakobsen, B.K. (2000). Molecular interactions of coreceptor CD8 and MHC class I: the molecular basis for functional coordination with the T-cell receptor. Immunol Today 21, 630–636 10.1016/S0167-5699(00)01750-3.
[16] Garboczi, D.N., Hung, D.T., and Wiley, D.C. (1992). HLA-A2-peptide complexes: refolding and crystallization of molecules expressed in Escherichia coli and complexed with single antigenic peptides. Proc Natl Acad Sci USA 89, 3429–3433 10.1073/pnas.89.8.3429.
[17] Hamerman, J.A., and Lanier, L.L. (2006). Inhibition of immune responses by ITAM-bearing receptors.PMID: 16449667Sci STKE 2006, re110.1126/stke.3202006re1.
[18] Ivashkiv, L.B. (2009). Cross-regulation of signaling by ITAM-associated receptors. Nat Immunol 10, 340–347 10.1038/ni.1706.
[19] Kerry, S.E., Buslepp, J., Cramer, L.A., Maile, R., Hensley, L.L., Nielsen, A.I., Kavathas, P., Vilen, B.J., Collins, E.J., and Frelinger, J.A. (2003). Interplay between TCR affinity and necessity of coreceptor ligation: high-affinity peptide-MHC/TCR interaction overcomes lack of CD8 engagement. J Immunol 171, 4493–4503 .
[20] Laugel, B., Price, D.A., Milicic, A., and Sewell, A.K. (2007). CD8 exerts differential effects on the deployment of cytotoxic T lymphocyte effector functions. Eur J Immunol 37, 905–913 10.1002/eji.200636718.
[21] Lepin, E.J., Bastin, J.M., Allan, D.S., Roncador, G., Braud, V.M., Mason, D.Y., van der Merwe, P.A., McMichael, A.J., Bell, J.I., Powis, S.H., (2000). Functional characterization of HLA-F and binding of HLA-F tetramers to ILT2 and ILT4 receptors. Eur J Immunol 30, 3552–3561 10.1002/1521-4141(200012)30:12<3552::AID-IMMU3552>3.0.CO;2-L.
[22] Li, Y., Moysey, R., Molloy, P.E., Vuidepot, A.L., Mahon, T., Baston, E., Dunn, S., Liddy, N., Jacob, J., Jakobsen, B.K., (2005). Directed evolution of human T-cell receptors with picomolar affinities by phage display. Nat Biotechnol 23, 349–354 10.1038/nbt1070.
[23] McCafferty, J., Griffiths, A.D., Winter, G., and Chiswell, D.J. (1990). Phage antibodies: filamentous phage displaying antibody variable domains. Nature 348, 552–554 10.1038/348552a0.
[24] McNicol, A.M., Bendle, G., Holler, A., Matjeka, T., Dalton, E., Rettig, L., Zamoyska, R., Uckert, W., Xue, S.A., and Stauss, H.J. (2007). CD8alpha/alpha homodimers fail to function as co-receptor for a CD8-dependent TCR. Eur J Immunol 37, 1634–1641 10.1002/eji.200636900.
[25] Natarajan, K., Dimasi, N., Wang, J., Mariuzza, R.A., and Margulies, D.H. (2002). Structure and function of natural killer cell receptors: multiple molecular solutions to self, nonself discrimination. Annu Rev Immunol 20, 853–885 10.1146/annurev.immunol.20.100301.064812.
[26] Navarro, F., Llano, M., Bellon, T., Colonna, M., Geraghty, D.E., and Lopez-Botet, M. (1999). The ILT2(LIR1) and CD94/NKG2A NK cell receptors respectively recognize HLA-G1 and HLA-E molecules co-expressed on target cells. Eur J Immunol 29, 277–283 10.1002/(SICI)1521-4141(199901)29:01<277::AID-IMMU277>3.0.CO;2-4.
[27] Roberts, M.J., Bentley, M.D., and Harris, J.M. (2002). Chemistry for peptide and protein PEGylation. Adv Drug Deliv Rev 54, 459–476 10.1016/S0169-409X(02)00022-4.
[28] Saverino, D., Fabbi, M., Ghiotto, F., Merlo, A., Bruno, S., Zarcone, D., Tenca, C., Tiso, M., Santoro, G., Anastasi, G., (2000). The CD85/LIR-1/ILT2 inhibitory receptor is expressed by all human T lymphocytes and down-regulates their functions. J Immunol 165, 3742–3755 .
[29] Sewell, A.K., Gerth, U.C., Price, D.A., Purbhoo, M.A., Boulter, J.M., Gao, G.F., Bell, J.I., Phillips, R.E., and Jakobsen, B.K. (1999). Antagonism of cytotoxic T-lymphocyte activation by soluble CD8. Nat Med 5, 399–404 10.1038/7398.
[30] Veronese, F.M., and Mero, A. (2008). The impact of PEGylation on biological therapies. BioDrugs 22, 315–329 10.2165/00063030-200822050-00004.
[31] Willcox, B.E., Gao, G.F., Wyer, J.R., O'Callaghan, C.A., Boulter, J.M., Jones, E.Y., van der Merwe, P.A., Bell, J.I., and Jakobsen, B.K. (1999). Production of soluble alphabeta T-cell receptor heterodimers suitable for biophysical analysis of ligand binding. Protein Sci 8, 2418–2423 10.1110/ps.8.11.2418.
[32] Willcox, B.E., Thomas, L.M., and Bjorkman, P.J. (2003). Crystal structure of HLA-A2 bound to LIR-1, a host and viral major histocompatibility complex receptor. Nat Immunol 4, 913–919 10.1038/ni961.
[33] Willcox, B.E., Thomas, L.M., Chapman, T.L., Heikema, A.P., West, A.P. Jr, and Bjorkman, P.J. (2002). Crystal structure of LIR-2 (ILT4) at 1.8 A: differences from LIR-1 (ILT2) in regions implicated in the binding of the Human Cytomegalovirus class I MHC homolog UL18. BMC Struct Biol 2, 610.1186/1472-6807-2-6.
[34] Wyer, J.R., Willcox, B.E., Gao, G.F., Gerth, U.C., Davis, S.J., Bell, J.I., van der Merwe, P.A., and Jakobsen, B.K. (1999). T cell receptor and coreceptor CD8 alphaalpha bind peptide-MHC independently and with distinct kinetics. Immunity 10, 219–225 10.1016/S1074-7613(00)80022-9.
[35] Zhang, Y., Liu, Y., Moxley, K.M., Golden-Mason, L., Hughes, M.G., Liu, T., Heemskerk, M.H., Rosen, H.R., Nishimura, M.I., and Gale, M. (2010). Transduction of human T cells with a novel T-cell receptor confers anti-HCV reactivity. PLoS Pathog 6, e100101810.1371/journal.ppat.1001018.